Display options
Share it on

J Venom Anim Toxins Incl Trop Dis. 2014 Apr 16;20:15. doi: 10.1186/1678-9199-20-15. eCollection 2014.

Systemic effects induced by intralesional injection of ω-conotoxin MVIIC after spinal cord injury in rats.

The journal of venomous animals and toxins including tropical diseases

Karen M Oliveira, Carla Maria O Silva, Mário Sérgio L Lavor, Isabel R Rosado, Fabíola B Fukushima, Anna Luiza Fv Assumpção, Saira Mn Neves, Guilherme R Motta, Fernanda F Garcia, Marcus Vinícius Gomez, Marília M Melo, Eliane G Melo

Affiliations

  1. Departamento de Clínica e Cirurgia Veterinária, Escola de Veterinária, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Pampulha, Belo Horizonte, MG CEP 30123-970, Brasil.
  2. Departament of Agrarian and Environmental Sciences, State University of Santa Cruz, Ilhéus, Bahia State, Brazil.
  3. National Institute of Sciences and Technology on Molecular Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais State, Brazil.

PMID: 24739121 PMCID: PMC4021631 DOI: 10.1186/1678-9199-20-15

Abstract

BACKGROUND: Calcium channel blockers such as conotoxins have shown a great potential to reduce brain and spinal cord injury. MVIIC neuroprotective effects analyzed in in vitro models of brain and spinal cord ischemia suggest a potential role of this toxin in preventing injury after spinal cord trauma. However, previous clinical studies with MVIIC demonstrated that clinical side effects might limit the usefulness of this drug and there is no research on its systemic effects. Therefore, the present study aimed to investigate the potential toxic effects of MVIIC on organs and to evaluate clinical and blood profiles of rats submitted to spinal cord injury and treated with this marine toxin. Rats were treated with placebo or MVIIC (at doses of 15, 30, 60 or 120 pmol) intralesionally following spinal cord injury. Seven days after the toxin administration, kidney, brain, lung, heart, liver, adrenal, muscles, pancreas, spleen, stomach, and intestine were histopathologically investigated. In addition, blood samples collected from the rats were tested for any hematologic or biochemical changes.

RESULTS: The clinical, hematologic and biochemical evaluation revealed no significant abnormalities in all groups, even in high doses. There was no significant alteration in organs, except for degenerative changes in kidneys at a dose of 120 pmol.

CONCLUSIONS: These findings suggest that MVIIC at 15, 30 and 60 pmol are safe for intralesional administration after spinal cord injury and could be further investigated in relation to its neuroprotective effects. However, 120 pmol doses of MVIIC may provoke adverse effects on kidney tissue.

Keywords: Biochemistry; Cone snail; Conus magus; Hematology; Histopathology

References

  1. Annu Rev Biochem. 1994;63:823-67 - PubMed
  2. Brain Res. 1999 Jan 30;817(1-2):84-92 - PubMed
  3. Cell Transplant. 2011;20(5):727-39 - PubMed
  4. NeuroRx. 2004 Jan;1(1):80-100 - PubMed
  5. J Biol Chem. 1996 Jun 7;271(23):13804-10 - PubMed
  6. J Neurosci. 2007 Oct 31;27(44):11782-92 - PubMed
  7. Br J Pharmacol. 1996 Sep;119(1):49-56 - PubMed
  8. Curr Treat Options Neurol. 2004 Mar;6(2):115-123 - PubMed
  9. Toxicol Pathol. 1986;14(1):37-44 - PubMed
  10. Spine (Phila Pa 1976). 2000 Jul 15;25(14):1859-66 - PubMed
  11. J Gen Physiol. 2002 Apr;119(4):313-28 - PubMed
  12. Surg Neurol. 1995 May;43(5):484-5 - PubMed
  13. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7076-80 - PubMed
  14. Int J Exp Pathol. 2010 Dec;91(6):530-6 - PubMed
  15. Pain. 2011 Oct;152(10):2224-2232 - PubMed
  16. J Neuroimmunol. 1997 Nov;79(2):211-7 - PubMed
  17. Brain Res Brain Res Rev. 2004 May;45(2):125-41 - PubMed
  18. J Am Vet Med Assoc. 1990 Aug 15;197(4):483-7 - PubMed
  19. Br J Anaesth. 2005 Jan;94(1):18-23 - PubMed
  20. Neurosurgery. 1999 May;44(5):1027-39; discussion 1039-40 - PubMed
  21. Neuropathology. 2011 Feb;31(1):48-58 - PubMed
  22. Pathol Res Pract. 2011 Dec 15;207(12):775-9 - PubMed
  23. J Neurobiol. 1992 Nov;23(9):1261-76 - PubMed
  24. NeuroRx. 2005 Oct;2(4):662-70 - PubMed
  25. FEBS Lett. 2001 Feb 23;491(1-2):127-30 - PubMed
  26. Am J Kidney Dis. 1999 May;33(5):899-903 - PubMed
  27. Toxicon. 1998 Feb;36(2):391-403 - PubMed
  28. Hippocampus. 2009 Nov;19(11):1123-9 - PubMed
  29. J Neurosci Res. 2011 Jun;89(6):791-801 - PubMed
  30. Inj Prev. 2002 Dec;8 Suppl 4:IV33-6 - PubMed
  31. Asia Pac J Public Health. 2010 Jan;22(1):9-18 - PubMed
  32. Toxicon. 1997 Aug;35(8):1161-91 - PubMed
  33. J Trauma. 2009 May;66(5):1349-54 - PubMed
  34. Neuron. 1992 Jul;9(1):69-77 - PubMed
  35. J Neurosci. 1994 Aug;14(8):4882-90 - PubMed
  36. Spine J. 2002 Mar-Apr;2(2):116-28 - PubMed
  37. J Pharmacol Exp Ther. 1996 Dec;279(3):1243-9 - PubMed
  38. Rev Bras Ter Intensiva. 2007 Jun;19(2):182-5 - PubMed
  39. J Bone Joint Surg Br. 1991 Jul;73(4):687-8 - PubMed

Publication Types